Kentucky reaches OxyContin, Risperdal settlements; Valeant's Walgreens pact won't solve its growth problems;

> Kentucky has reached two separate settlements totaling $39.5 million--one each with Purdue and Johnson & Johnson ($JNJ) over their respective meds, OxyContin and Risperdal. More

> Valeant's ($VRX) new pricing and distribution pact with Walgreens ($WBA) likely won't bring the company the same revenue growth it generated with high-priced branded drugs, doctors and investors say. More

> India has added drugs for cancer, HIV/AIDS and hepatitis C to its essential medicines list in hopes of making them more affordable. More

> The New England Journal of Medicine has published positive results of two trials of Novartis' ($NVS) Cosentyx in ankylosing spondylitis. Release

And Finally... The U.S. Drug Enforcement Agency (DEA) is easing the regulatory requirements that were previously imposed on those conducting FDA-approved clinical trials on cannabidiol. More

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.